Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1006667

registered interest
date	13/11/2018
answering body	Department for Digital, Culture, Media and Sport
answering dept id	10
answering dept short name	Digital, Culture, Media and Sport
answering dept sort name	Digital, Culture, Media and Sport
hansard heading	Museums and Galleries: Copyright
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Written Answer by Lord Ashton of Hyde on 12 November (HL11086), which stated that "Complaints about charges for re-use by museums and galleries may be referred to the Information Commissioner for a binding decision”, whether this is consistent with the Information Commissioner’s Office (ICO)’s Guide to RPSI, which states that it “can issue a decision notice, unless the complaint concerns charges above marginal cost, in which case we make a non-binding recommendation”, and the ICO’s Decision Notice FS50619465 of 4 April 2017, which states that it can “only make recommendations in respect of any charges levied under the RPSI.
tabling member printed	Lord Freyberg
uin	HL11447
answer	answer is ministerial correction date of answer 26/11/2018 answer text <p>The Information Commissioner’s (ICO) guidance summarises the general issue of charging for re-use, but does not go into specific details beyond this.</p><p> </p><p>Regulation 19 of RPSI states that in the case of bodies subject to regulations 15 (3) (a) or (b), complaints about re-use charges are subject to recommendation only by the Information Commissioner and appeals against recommendations can lead to a binding decision at tribunal.</p><p> </p><p>Museums and galleries’ charging falls under regulation 15 (3) (c), meaning that the usual redress route of a binding decision by the Information Commissioner applies.</p><p> </p><p>The ICO have confirmed they will be updating their guidance to make this clear.</p> answering member printed Lord Ashton of Hyde question first answered 26/11/2018 12:11:06 answering member 4247 label Biography information for Lord Ashton of Hyde
tabling member	2593 label Biography information for Lord Freyberg

1006668

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government which cancers have been recommended by NICE for molecular testing; and of those cancers, for which biomarkers in relation to (1) prognostic tests, and (2) theranostic or treatment predictive tests.
tabling member printed	Lord Freyberg
uin	HL11448
answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) recommends molecular testing for the following cancers:</p><p>- Acute myeloid leukaemia;</p><p>- Bladder;</p><p>- Brain;</p><p>- Breast;</p><p>- Chronic lymphocytic leukaemia;</p><p>- Chronic myeloid leukaemia;</p><p>- Colorectal;</p><p>- Non-small-cell lung cancer;</p><p>- Melanoma;</p><p>- Oesophago-gastric;</p><p>- Ovarian, fallopian tube and peritoneal;</p><p>- Pancreatic;</p><p>- Prostate;</p><p>- Upper aerodigestive tract; and</p><p>- Unknown primary origin.</p><p>NICE refers to the following companion diagnostic biomarkers in its guidance:</p><p>- c-Kit (CD117);</p><p>- HER2;</p><p>- KRAS;</p><p>- EGFR-TK;</p><p>- Philadelphia chromosome;</p><p>- BRAF V600;</p><p>- ALK;</p><p>- BRCA;</p><p>- p53;</p><p>- PD-L1;</p><p>- RAS;</p><p>- BCR-ABL1;</p><p>- FLT3;</p><p>- ROS1;</p><p>- BRCA1 (germline); and</p><p>- Somatostatin receptor-positive.</p><p> </p><p>Tests that are primarily used for diagnosis, monitoring or screening often provide prognostic information. Consequently, there are a large number of biomarkers, many of which are used in standard testing practice and so are not specifically referred to in NICE guidance. Multiple and combinations of biomarkers are often used to provide prognostic information and companies developing tests often create their own combinations.</p><p>As many tests look for multiple biomarkers for a single purpose and many tests in standard practice provide prognostic information, NICE is unable to provide categorical information on prognostic tests.</p> answering member printed Lord O'Shaughnessy question first answered 27/11/2018 15:29:48 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2593 label Biography information for Lord Freyberg

1006669

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government which NHS England trusts currently carry out cancer tests in compliance with NICE guidelines; and in relation to which cancers.
tabling member printed	Lord Freyberg
uin	HL11449
answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>NHS England does not hold this information.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11450 HL11451 question first answered 27/11/2018 15:48:20 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2593 label Biography information for Lord Freyberg

1006670

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government which NHS England trusts, if any, have secured funding to test for cancers clinically beyond the NICE guidelines, including through use of theranostic tests and somatic gene panels that can report back to patients within a clinically actionable time frame; and in relation to which cancers.
tabling member printed	Lord Freyberg
uin	HL11450
answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>NHS England does not hold this information.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11449 HL11451 question first answered 27/11/2018 15:48:20 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2593 label Biography information for Lord Freyberg

1006671

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the main reasons for non-compliance with NICE guidelines for testing for cancer by NHS England trusts.
tabling member printed	Lord Freyberg
uin	HL11451
answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>NHS England does not hold this information.</p> answering member printed Lord O'Shaughnessy grouped question UIN HL11449 HL11450 question first answered 27/11/2018 15:48:20 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2593 label Biography information for Lord Freyberg

1006672

registered interest
date	13/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what progress they have made towards the Cancer Task Force’s recommendation for a national molecular pathology service; and when they anticipate to implement this fully in relation to adult cancer diagnosis and care.
tabling member printed	Lord Freyberg
uin	HL11452
answer	answer is ministerial correction date of answer 27/11/2018 answer text <p>In 2015, the Independent Cancer Taskforce Report highlighted limited access to molecular diagnostics across the National Health Service and limited use of technology to systematically identify patients with cancer and suggested that this has resulted in the NHS falling behind other countries in the delivery of high-quality, cost-effective cancer care.</p><p>To address this, building on the world leading 100,000 Genomes Project and the existing infrastructure, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The GMS will bring together existing clinical genetics services and the new genomic laboratory infrastructure to provide seamless service delivery for patients with rare and inherited disease and cancer.</p> answering member printed Lord O'Shaughnessy question first answered 27/11/2018 15:48:42 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	2593 label Biography information for Lord Freyberg